TScan Therapeutics Analyst Ratings
TScan Therapeutics: A Promising Future in Cell Therapy With Buy Rating and $12 Target
TScan Therapeutics Analyst Ratings
Buy Rating Affirmed: TScan Therapeutics' Innovative TCR-T Therapy and Strategic Milestones Promising for 2024
Analysts Are Bullish on These Healthcare Stocks: Apellis Pharmaceuticals (APLS), TScan Therapeutics (TCRX)
Promising Clinical Results and Robust Financial Position Warrant a Buy Rating for TScan Therapeutics
TScan Therapeutics Analyst Ratings
TScan Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Zoetis (ZTS) and TScan Therapeutics (TCRX)
TScan Therapeutics Analyst Ratings
Barclays Sticks to Their Buy Rating for TScan Therapeutics (TCRX)
Buy Rating Affirmed for TScan Therapeutics Following Promising Phase 1 Results
Wedbush Adjusts TScan Therapeutics Price Target to $10 From $9, Maintains Outperform Rating
Strong Buy Rating for TScan Therapeutics Backed by Positive Phase 1 Trial Data and Promising Treatment Efficacy
TScan Therapeutics (TCRX) Receives a Buy From Barclays
Buy Rating for TScan Therapeutics Supported by Iovance's FDA Approval and Promising TIL Therapy Benchmark
TScan Therapeutics Analyst Ratings
Strong Buy Rating for TScan Therapeutics Amid Progressive Clinical Advancements
Wedbush Lifts TScan Therapeutics' Price Target to $9 From $8, Keeps Outperform Rating
Buy Rating Reiteration for TScan Therapeutics: Advancements in TCR-T Cell Therapy and Expansion of ImmunoBank Portfolio
No Data